456 related articles for article (PubMed ID: 15009714)
1. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H; Goel V; Wu H; Yang G; Haluska FG
J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
[TBL] [Abstract][Full Text] [Related]
2. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
3. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
4. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
5. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
6. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Tsao H; Zhang X; Benoit E; Haluska FG
Oncogene; 1998 Jul; 16(26):3397-402. PubMed ID: 9692547
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg P; thor Straten P; Birck A; Ahrenkiel V; Kirkin AF; Zeuthen J
Cancer Res; 1997 Sep; 57(17):3660-3. PubMed ID: 9288767
[TBL] [Abstract][Full Text] [Related]
8. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
9. PTEN/MMAC1 expression in melanoma resection specimens.
Deichmann M; Thome M; Benner A; Egner U; Hartschuh W; Näher H
Br J Cancer; 2002 Dec; 87(12):1431-6. PubMed ID: 12454773
[TBL] [Abstract][Full Text] [Related]
10. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
11. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival.
Akslen LA; Angelini S; Straume O; Bachmann IM; Molven A; Hemminki K; Kumar R
J Invest Dermatol; 2005 Aug; 125(2):312-7. PubMed ID: 16098042
[TBL] [Abstract][Full Text] [Related]
12. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
13. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
14. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
15. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutations are common somatic events in melanocytic nevi.
Kumar R; Angelini S; Snellman E; Hemminki K
J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
18. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.
Birck A; Ahrenkiel V; Zeuthen J; Hou-Jensen K; Guldberg P
J Invest Dermatol; 2000 Feb; 114(2):277-80. PubMed ID: 10651986
[TBL] [Abstract][Full Text] [Related]
19. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression.
Poetsch M; Dittberner T; Woenckhaus C
Cancer Genet Cytogenet; 2001 Feb; 125(1):21-6. PubMed ID: 11297763
[TBL] [Abstract][Full Text] [Related]
20. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
